MedTrace Logo

mHealth ALIBIRD: A Digital Health Care Model

NCT05770869 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-10-18

No results posted yet for this study

Summary

The aim of this pilot study was to evaluate the feasibility and acceptability of the ALIBIRD platform, a new mobile health (mHealth) application prototype design for personalized and remote support on the follow-up of cancer patients. The ALIBIRD platform is a mHealth intervention that tracks PROs, improving symptom control and allowing real-time feedback, and provides personalized recommendations and educational content, promoting empowerment and encourage healthy lifestyle behaviors in patients with thoracic neoplasms in active treatment.

Conditions

  • Thoracic Neoplasms

Interventions

DEVICE

ALIBIRD mHealth platform

Use of a mHealth platform to follow-up and empower cancer patients in the self-management of their own health.

Sponsors & Collaborators

  • Hospital Infanta Sofia

    collaborator OTHER

  • Universidad Politecnica de Madrid

    collaborator OTHER

  • IMDEA Food

    collaborator OTHER

  • Instituto de Investigación en Ciencias de la Alimentación (CIAL)

    collaborator UNKNOWN

  • Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares

    lead OTHER

Principal Investigators

  • María Sereno Moyano, Medicine · Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-05
Primary Completion
2022-10-28
Completion
2022-10-28

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05770869 on ClinicalTrials.gov